Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Market Closed 12-12 16:00:00 EST

14.56

-0.01

-0.07%

盘后14.61

+0.05+0.34%

19:22 EST

High16.45	Low14.51	Vol1.24M
Open15.22	D1 Closing14.57	Amplitude13.32%
Mkt Cap1.04B	Tradable Cap756.39M	Total Shares71.14M
T/O18.87M	T/O Rate2.40%	Tradable Shares51.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":14.56,"timestamp":1765573200000,"preClose":14.57,"halted":0,"volume":1244387,"hourTrading":{"tag":"盘后","latestPrice":14.61,"preClose":14.56,"latestTime":"19:22 EST","volume":19132,"amount":278659.74,"timestamp":1765585360165},"delay":0,"floatShares":51950100,"shares":71138440,"eps":-3.801026,"marketStatus":"Market Closed","change":-0.01,"latestTime":"12-12 16:00:00 EST","open":15.22,"high":16.45,"low":14.51,"amount":18872939.438084997,"amplitude":0.13315,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.801026,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":14.57,"preHourTrading":{"tag":"盘前","latestPrice":15.12,"preClose":14.57,"latestTime":"09:26 EST","volume":2046,"amount":30687.446592,"timestamp":1765549590036},"postHourTrading":{"tag":"盘后","latestPrice":14.61,"preClose":14.56,"latestTime":"19:22 EST","volume":19132,"amount":278659.74,"timestamp":1765585360165},"volumeRatio":1.875110538883407,"impliedVol":0.6992,"impliedVolPercentile":0.148},"requestUrl":"/m/hq/s/PHAT/wiki","defaultTab":"wiki","newsList":[{"id":"2590509174","title":"Raymond James Initiates Phathom Pharmaceuticals at Strong Buy With $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590509174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590509174?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:07","pubTimestamp":1765544869,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) has an average rating of buy and mean price target of $22.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RJF","PHAT"],"gpt_icon":0},{"id":"2590634624","title":"Barclays Initiates Phathom Pharmaceuticals at Equalweight With $16 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590634624","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590634624?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:54","pubTimestamp":1765284881,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) has an average rating of buy and mean price target of $22.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAT"],"gpt_icon":0},{"id":"2589730928","title":"Indonesia Probes 12 Legal Entities Over Forest Destruction Behind Sumatra Floods","url":"https://stock-news.laohu8.com/highlight/detail?id=2589730928","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589730928?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:00","pubTimestamp":1765026000,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -The Directorate General of Law Enforcement under Indonesia’s Ministry of Environment and Forestry is investigating 12 legal entities suspected of damaging forests in the upstream ar","market":"hk","thumbnail":"https://statik.tempo.co/data/2025/08/14/id_1420917/1420917_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/08/14/id_1420917/1420917_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2071490/indonesia-probes-12-legal-entities-over-forest-destruction-behind-sumatra-floods","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2071490/indonesia-probes-12-legal-entities-over-forest-destruction-behind-sumatra-floods","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2583531062","title":"Phathom Pharmaceuticals (PHAT): Assessing Valuation After First Patient Dosed in VOQUEZNA EoE Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2583531062","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583531062?lang=en_us&edition=fundamental","pubTime":"2025-11-13 10:21","pubTimestamp":1763000480,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) has started dosing the first patient in its Phase 2 clinical trial for VOQUEZNA, targeting eosinophilic esophagitis in adults. This marks a meaningful step in broadening the therapeutic reach of VOQUEZNA.\nSee our latest analysis for Phathom Pharmaceuticals.\nThat milestone comes in the wake of a few busy weeks for Phathom Pharmaceuticals, including conference presentations and improved revenue guidance for 2025. The 1-year total shareholder return of nearly 50%...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/phathom-pharmaceuticals-phat-assessing-valuation-after-first","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/phathom-pharmaceuticals-phat-assessing-valuation-after-first","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2580734528","title":"Phathom Pharmaceuticals Inc - Topline Results Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2580734528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580734528?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUACBCRHB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2580731253","title":"Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731253?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUACBCRHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2580129734","title":"Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580129734","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580129734?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261200,"startTime":"0","endTime":"0","summary":"First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov.  04, 2025  (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180287/0/en/Phathom-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-2-Study-of-VOQUEZNA-vonoprazan-in-Eosinophilic-Esophagitis-EoE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","BK4007","PHAT","TEN","BK4144"],"gpt_icon":0},{"id":"2580735235","title":"Phathom Pharmaceuticals Inc - Topline Results of Phase 2 Eoe Study Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735235?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:10","pubTimestamp":1762258212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG0Q3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2580187642","title":"Phathom Pharmaceuticals to Present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580187642","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580187642?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:59","pubTimestamp":1762174767,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals Inc. will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA on November 10, 2025. Members of the management team will take part in one-on-one meetings throughout the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL5TFx9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4007","LU0314104364.USD","BK4585","LU2095319765.USD","LU2210150020.SGD","PHAT","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2580591445","title":"Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2580591445","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580591445?lang=en_us&edition=fundamental","pubTime":"2025-11-01 09:19","pubTimestamp":1761959966,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc. (($PHAT)) has held its Q3 earnings call. Read on for the main highlights of the call. Phathom Pharmaceuticals’ recent...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-q3-earnings-strong-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-q3-earnings-strong-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"gpt_icon":0},{"id":"1183439452","title":"Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1183439452","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183439452?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:35","pubTimestamp":1761917700,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) stock is surging 8.41% in early trading on Friday, building on its pre-market momentum following the release of its third-quarter 2025 earnings report and a positive...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0},{"id":"1107908806","title":"Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1107908806","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107908806?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:34","pubTimestamp":1761917690,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) stock is soaring 8.41% in pre-market trading on Friday, following the release of its third-quarter 2025 earnings report and positive analyst updates. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0},{"id":"1159604203","title":"Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1159604203","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159604203?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:28","pubTimestamp":1761917299,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) stock is surging 5.79% in pre-market trading on Friday, following the release of its third-quarter 2025 earnings report and a positive analyst update. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0},{"id":"1128129861","title":"Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1128129861","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128129861?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:28","pubTimestamp":1761917298,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) saw its stock surge 5.79% in pre-market trading on Friday, following the release of its third-quarter earnings report for 2025 and a positive analyst update. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0},{"id":"2579468095","title":"Phathom Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2579468095","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579468095?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:00","pubTimestamp":1761908400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2025 07:00 ET (11:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2579864176","title":"Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2579864176","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579864176?lang=en_us&edition=fundamental","pubTime":"2025-10-31 02:45","pubTimestamp":1761849932,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals, with a price target of $28.00. Joseph ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/phathom-pharmaceuticals-strong-q3-performance-and-promising-growth-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/phathom-pharmaceuticals-strong-q3-performance-and-promising-growth-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"gpt_icon":0},{"id":"1123880806","title":"Stock Track | Phathom Pharmaceuticals Soars 10.50% Pre-Market on Strong Q3 Results and Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1123880806","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123880806?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:08","pubTimestamp":1761833331,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (NASDAQ: PHAT) stock is soaring 10.50% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The pharmaceutical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0},{"id":"1137667451","title":"Stock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1137667451","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137667451?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:08","pubTimestamp":1761833329,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (NASDAQ: PHAT) stock is soaring 10.50% in pre-market trading following the release of its impressive third-quarter 2025 financial results. The pharmaceutical company...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0},{"id":"2579237991","title":"Craig-Hallum Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2579237991","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579237991?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:05","pubTimestamp":1761833158,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Phathom Pharmaceuticals today. The company’s shares opened today at $14.00. Kni...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-phathom-pharmaceuticals-phat-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-phathom-pharmaceuticals-phat-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"gpt_icon":0},{"id":"1183151621","title":"Stock Track | Phathom Pharmaceuticals Soars 6.43% Pre-market on Strong Q3 Results and Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1183151621","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183151621?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:02","pubTimestamp":1761825758,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) stock surged 6.43% in pre-market trading following the release of its impressive third-quarter 2025 financial results. The pharmaceutical company significantly...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.0041},{"period":"3month","weight":0.2297},{"period":"6month","weight":0.3684},{"period":"1year","weight":0.8234},{"period":"ytd","weight":0.7931}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.063425},{"month":2,"riseRate":0.666667,"avgChangeRate":0.0903},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.119883},{"month":4,"riseRate":0.5,"avgChangeRate":0.053339},{"month":5,"riseRate":0.5,"avgChangeRate":-0.02431},{"month":6,"riseRate":0.666667,"avgChangeRate":0.246775},{"month":7,"riseRate":0.666667,"avgChangeRate":0.025067},{"month":8,"riseRate":0.666667,"avgChangeRate":0.15186},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003613},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.040055},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.100392},{"month":12,"riseRate":0.571429,"avgChangeRate":0.052376}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction